Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02962661 · ClinicalTrials.gov registry record · Phase 1

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

A Phase 1 study of Heart Failure and Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
72
Enrollment target
1
Study location

NCT02962661: Recruiting Phase 1 study of Heart Failure and Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center.

NCT02962661 is a Phase 1 study of Heart Failure and Malignant Solid Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 72 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02962661, a Phase 1 study of Heart Failure and Malignant Solid Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
72 participants
Enrollment target
1
Study location

Study Summary

This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and improve heart function.

Conditions Studied

Heart Failure Malignant Solid Neoplasm Hematopoietic and Lymphoid Cell Neoplasm Cardiomyopathy

Interventions

  • OTHER Laboratory Biomarker Analysis
  • OTHER Best Practice
  • DRUG Mesenchymal Stem Cell Transplantation

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2020-07-18
Est. Completion 2026-07-30
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What NCT02962661 shows while recruiting

NCT02962661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower).

The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02962661 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT02962661 about?

NCT02962661 is a clinical study titled "Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines". This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and i...

What is the current status of trial NCT02962661?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2020-07-18. Estimated completion is 2026-07-30.

What conditions does trial NCT02962661 study?

This clinical trial studies the following conditions: Heart Failure, Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Cardiomyopathy.

What interventions are being tested in trial NCT02962661?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Best Practice (OTHER), Mesenchymal Stem Cell Transplantation (DRUG).

Who is sponsoring clinical trial NCT02962661?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02962661 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02962661's enrollment target sits among peer trials

72 240th of 397 higher than 156 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02359253 · 72 participants · NA

    Robot Aided Rehabilitation - Intervention

  • NCT03113643 · 72 participants · Phase 1

    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • NCT03187535 · 72 participants · NA

    Effect of TEAS on PONV After Spinal Surgery

  • NCT03747458 · 72 participants · Phase 3

    OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT02962661

Source: ClinicalTrials.gov NCT02962661, the US trial registry maintained by the National Library of Medicine. NCT02962661 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.